AU 105

Drug Profile

AU 105

Alternative Names: AU105

Latest Information Update: 12 Jul 2016

Price : $50

At a glance

  • Originator Aurora BioPharma
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Discontinued Sarcoma

Most Recent Events

  • 12 Jul 2016 Discontinued - Phase-I/II for Sarcoma in USA (IV)
  • 05 Jul 2016 Aurora BioPharma completes a phase Ib/IIa trial in Glioblastoma (Newly diagnosed) in USA (Aurora BioPharma pipeline) before July 2016
  • 06 Jun 2016 Aurora BioPharma plans a phase IIb/III trial for Glioblastoma (Newly diagnosed) (Aurora BioPharma Presentation, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top